Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 14 clinical trials
Fuzuloparib Arsenic Trioxide Platinum Resistance Relapsed Ovarian Cancer

Ovarian cancer is the leading cause of death from gynecologic tumors in the western world. Most patients have relapses, and responses to subsequent therapies are generally short-lived. Currently, the population that can benefit from PARPi is mainly focusing on BRCAm, then homologous-recombination deficiency patients. Limited data revealed the ORR was …

  • 0 views
  • 25 Mar, 2022
  • 1 location
Predicting Olaparib Sensitivity in Patients With Unresectable Locally Advanced/Metastatic HER2-negative Breast Cancer. (RADIOLA)

The primary objetive is to assess the capacity of the RAD51-foci score to predict the efficacy of olaparib in BRCA1/2, PALB2 or RAD51C/D mut advanced breast cancer (cohort 1). The

BRCA1
RAD51
advanced breast cancer
erbb2
BRCA1/2
  • 0 views
  • 04 May, 2022
  • 2 locations
Functional Analysis of BRCAness

(RAD51 assay;) to test HR in viable tumor tissue. In the proposed study, we will evaluate whether the RAD51 assay predicts sensitivity to therapy with olaparib, in patients with recurrent EOC. With the

  • 0 views
  • 09 Apr, 2021
  • 3 locations
Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations

This phase II trial studies how well olaparib works in treating patients with biliary tract cancer that has spread to other places in the body (metastatic) and with aberrant DNA repair gene mutations. Olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell …

serum pregnancy test
olaparib
blood transfusion
tumor cells
luteinizing hormone (lh)
  • 0 views
  • 29 May, 2022
  • 5 locations
Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects

This phase II trial studies how well niraparib, when given before surgery, works in treating patients with high risk prostate cancer that has not spread to other parts of the body (localized) and alterations in deoxyribonucleic acid (DNA) repair pathways. Niraparib may stop the growth of tumor cells by blocking …

niraparib
tumor cells
cancer
platelet count
absolute neutrophil count
  • 6 views
  • 21 Mar, 2022
  • 1 location
A Phase II Study of Olaparib (AZD2281) in Patients With Metastatic/Advanced Urothelial Carcinoma and Other Genitourinary Tumors With DNA-Repair Defects

This phase II trial studies how well olaparib works in treating patients with bladder cancer and other genitourinary tumors with deoxyribonucleic acid (DNA)-repair defects that has spread to other places in the body (advanced or metastatic) and usually cannot be cured or controlled with treatment. PARPs are proteins that help …

pembrolizumab
atezolizumab
nivolumab
cancer
TP53
  • 111 views
  • 19 Oct, 2022
  • 2 locations
The Trial Comparing Dose-dense AC-T With TP as Adjuvant Therapy for TNBC With Homologous Recombination Repair Deficiency

The purpose of this trial is to compare the 3-year disease-free survival of dose-dense epirubicin and cyclophosphamide followed by paclitaxel with paclitaxel plus carboplatin as adjuvant therapy for triple-negative breast cancer with homologous recombination repair deficiency. The other purpose of this trial is to observe the patient's tolerance.

  • 0 views
  • 22 Jan, 2021
  • 1 location
Cabozantinib and Pamiparib for the Treatment of Advanced of Refractory Solid Tumors

This phase I trial finds the best dose and side effects of cabozantinib and pamiparib in treating patients with solid tumors that have spread to other places in the body (advanced) or does not respond to treatment (refractory). Cabozantinib and pamiparib may stop the growth of tumor cells by blocking …

  • 0 views
  • 04 Oct, 2022
  • 1 location
A Phase 2 Single-Arm Study of M6620 in Combination With Irinotecan in Patients With Progressive TP53 Mutant Gastric and Gastro-Esophageal Junction Cancer

This phase II trial studies the how well berzosertib and irinotecan work in treating patients with gastric or gastroesophageal junction cancer that is growing, spreading or getting worse (progressive), has spread to other places in the body (metastatic), or cannot be removed by surgery (unresectable). Berzosertib may stop the growth …

  • 1 views
  • 24 Oct, 2022
  • 14 locations
Testing the Biological Effects of DS-8201a on Patients With Advanced Cancer

This phase I trial studies the biological effects of DS-8201a on patients with HER2 positive cancer that has spread to other places in the body (advanced). DS-8201a works by binding to a protein called HER2 that is present on the surface of tumor cells. This allows DS-8201a to kill the …

ds-8201a
brain metastases
liver metastasis
advanced cancer
tumor cells
  • 0 views
  • 07 Oct, 2022
  • 1 location